Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia

被引:13
|
作者
Ravnskov, Uffe [1 ]
de Lorgeril, Michel [2 ]
Kendrick, Malcolm [3 ]
Diamond, David M. [4 ,5 ]
机构
[1] Magle Stora Kyrkogata 9, S-22350 Lund, Sweden
[2] Univ Grenoble Alpes, CNRS, Lab Coeur & Nutr, TIMC,Fac Med, F-38056 La Tronche, France
[3] Macclesfield Hosp, East Cheshire Trust, Macclesfield, Cheshire, England
[4] Univ S Florida, Dept Psychol, Ctr Preclin & Clin Res PTSD, Tampa, FL 33620 USA
[5] Univ S Florida, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL USA
关键词
Familial hypercholesterolemia; LDL-cholesterol; HDL-cholesterol; Coronary heart disease; Cardiovascular disease; Coagulation; CORONARY-HEART-DISEASE; CAROTID ATHEROSCLEROSIS; DENSITY-LIPOPROTEIN; PLATELET-FUNCTION; ARTERY-DISEASE; ALIROCUMAB; EFFICACY; SAFETY; PROGRESSION; MORTALITY;
D O I
10.1016/j.mehy.2018.09.019
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
High low-density-lipoprotein cholesterol (LDL-C) is routinely described as the main cause of cardiovascular disease (CVD) in familial hypercholesterolemia (FH). However, numerous observations are in conflict with Bradford Hill's criteria for causality: a) degree of atherosclerosis is not associated with LDL-C; b) on average the life span of people with FH is about the same as for other people; c) LDL-C of people with FH without CVD is almost as high as in FH patients of the same age with CVD; and d) questionable benefit or none at all have been achieved in the controlled, randomized cholesterol-lowering trials that have included FH individuals only. Obviously, those individuals with FH who suffer from CVD may have inherited other and more important risk factors of CVD than high LDL-C. In accordance, several studies of FH individuals have shown that various coagulation factors may cause CVD. Equally, some non-FH members of an FH kindred with early CVD, have been found to suffer from early CVD as well. Cholesterol-lowering has only been successful in an animal experiment by using probucol, which has anticoagulant effects as well. We conclude that systematic studies of all kinds of risk factors among FH individuals are urgently required, because today millions of people with FH are treated with statins, the benefit of which in FH is unproven, and which have many serious side effects. We predict that treatment of FH individuals with elevated coagulation factors with anticoagulative drugs is more effective than statin treatment alone.
引用
收藏
页码:60 / 63
页数:4
相关论文
共 45 条
  • [31] Prevalence of high cholesterol levels suggestive of familial hypercholesterolemia in Brazilian adolescents: Data from the study of cardiovascular risk in adolescents
    Kaestner, Tatiana L.
    Bento, Vivian F.
    Pazin, Daiane C.
    Baena, Cristina P.
    Olandoski, Marcia
    Abreu, Gabriela A.
    Kuschnir, Maria Cristina C.
    Bloch, Katia V.
    Faria-Neto, Jose R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2018, 12 (02) : 403 - 408
  • [32] Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL
    Rallidis, Loukianos S.
    Kiouri, Estela
    Katsimardos, Andreas
    Kotakos, Christos
    ATHEROSCLEROSIS, 2018, 275 : 262 - 264
  • [33] Impact of High-Density Lipoprotein Function, Rather Than High-Density Lipoprotein Cholesterol Level, on Cardiovascular Disease Among Patients With Familial Hypercholesterolemia
    Tada, Hayato
    Okada, Hirofumi
    Nohara, Atsushi
    Toh, Ryuji
    Harada, Amane
    Murakami, Katsuhiro
    Iino, Takuya
    Nagao, Manabu
    Ishida, Tatsuro
    Hirata, Ken-ichi
    Takamura, Masayuki
    Kawashiri, Masa-aki
    CIRCULATION JOURNAL, 2023, 87 (06) : 806 - +
  • [34] Can the ESC/EAS LDL-cholesterol target in patients with diabetes and high cardiovascular risk be achieved in clinical practice? Results from an ambulatory multi-disciplinary diabetes center cohort
    Vidal-Trecan, T.
    Laloi-Michelin, M.
    Bouche, C.
    Juddoo, V.
    Dillinger, J. -G.
    Azancot, I.
    Kevorkian, J. -P.
    Sall, L.
    Feron, F.
    Henry, P.
    Gautier, J. F.
    Rivelinea, J. -.
    DIABETES & METABOLISM, 2019, 45 (06) : 592 - 595
  • [35] Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study
    Poli, Andrea
    Casula, Manuela
    Tragni, Elena
    Brignoli, Ovidio
    Filippi, Alessandro
    Cricelli, Claudio
    Catapano, Alberico L.
    PHARMACOLOGICAL RESEARCH, 2011, 64 (04) : 393 - 396
  • [36] Apolipoprotein B/A-I and total cholesterol/high-density lipoprotein cholesterol ratios both predict cardiovascular events in the general population independently of nonlipid risk factors, albuminuria and C-reactive protein
    Kappelle, P. J. W. H.
    Gansevoort, R. T.
    Hillege, J. L.
    Wolffenbuttel, B. H. R.
    Dullaart, R. P. F.
    JOURNAL OF INTERNAL MEDICINE, 2011, 269 (02) : 232 - 242
  • [37] Triglyceride and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease risk factors in Chinese Han children
    Wei Fen Zhu
    Li Liang
    Chun Lin Wang
    Jun Fen Fu
    Indian Pediatrics, 2013, 50 : 394 - 398
  • [38] Carotid intima-media thickness (IMT) in patients with severe familial and non-familial hypercholesterolemia: The effect of measurement site on the IMT correlation with traditional cardiovascular risk factors and calcium scores
    Galaska, Rafal
    Kulawiak-Galaska, Dorota
    Chmara, Magdalena
    Chlebus, Krzysztof
    Mickiewicz, Agnieszka
    Rynkiewicz, Andrzej
    Wasag, Bartosz
    Studniarek, Michal
    Fijalkowski, Marcin
    Gruchala, Marcin
    CARDIOLOGY JOURNAL, 2021, 28 (02) : 271 - 278
  • [39] Revising the fasting glucose threshold for detection of cardiovascular risk factors: analysing two representative population-based studies of more than 50 000 Iranians in 3 years: The National Survey of Risk Factors for Non-Communicable Diseases of Iran
    Esteghamati, Alireza
    Zandieh, Ali
    Hafezi-Nejad, Nima
    Sheikhbahaei, Sara
    Abbasi, Mehrshad
    Gouya, Mohamad M.
    Nakhjavani, Manouchehr
    ANNALS OF HUMAN BIOLOGY, 2015, 42 (02) : 150 - 158
  • [40] Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk: The influence of baseline medication on LDL-cholesterol, blood pressure and calculated risk reduction when switching to a cardiovascular polypill
    Lafeber, Melvin
    Spiering, Wilko
    Visseren, Frank L. J.
    Grobbee, Diederick E.
    Bots, Michiel L.
    Stanton, Alice
    Patel, Anushka
    Prabhakaran, Dorairaj
    Webster, Ruth
    Thom, Simon
    Rodgers, Anthony
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (09) : 951 - 961